nach oben

Erschienen in:

01.10.2010 | Scientific Article

Therapeutic impact of [¹⁸F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain

verfasst von: Dorothee Rita Fischer, Gerardo J. Maquieira, Norman Espinosa, Marco Zanetti, Rolf Hesselmann, Anass Johayem, Thomas F. Hany, Gustav K. von Schulthess, Klaus Strobel

Erschienen in: Skeletal Radiology | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the therapeutic impact of [¹⁸F]fluoride positron-emission tomography/computed tomography ([¹⁸F]fluoride PET/CT) imaging on patients with unclear foot pain.

Methods

Twenty-eight patients were prospectively included in this study. Therapeutic management was defined by two experienced dedicated foot surgeons before and after [¹⁸F]fluoride PET/CT imaging. Twenty-six patients underwent cross-sectional imaging [CT, magnetic resonance (MR)] prior to PET/CT. A retrospective analysis of the magnetic resonance imaging (MRI) diagnoses was performed when a therapy change occurred after PET/CT imaging.

Results

In 13/28 (46%) patients therapeutic management was changed due to PET/CT results. Management changes occurred in patients with the following diagnoses: os trigonum syndrome; sinus tarsi syndrome; os tibiale externum syndrome; osteoarthritis of several joints; non-consolidated fragments; calcaneo-navicular coalition; plantar fasciitis; insertional tendinopathy; suggestion of periostitis; neoarticulations between metatarsal bones. Os trigonum, os tibiale externum, subtalar osteoarthritis and plantar fasciitis were only seen to be active on PET/CT images but not on MR images.

Conclusion

[¹⁸F]fluoride PET/CT has a substantial therapeutic impact on management in patients with unclear foot pain.

Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68–78.PubMedCrossRef

Groves AM, Win T, Haim SB, Ell PJ. Non-(18F)FDG PET in clinical oncology (review). Lancet Oncol. 2007;8:822–30.PubMedCrossRef

Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–9.PubMedCrossRef

Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381–9.PubMed

Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800–4.PubMed

Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766–74.PubMedCrossRef

Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623–9.PubMed

Brenner W, Vernon C, Conrad EU, Eary JF. Assessment of the metabolic activity of bone grafts with 18F-fluoride PET. Eur J Nucl Med Mol Imaging. 2004;31:1291–8.PubMed

10.

Frost ML, Blake GM, Park-Holohan S-J, Cook GJR, Curran KM, Marsden PK, et al. Long-term precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. J Nucl Med. 2008;49:700–7.PubMedCrossRef

11.

Sterner T, Pink R, Freudenberg L, Jentzen T, Quitmann H, Bockisch A, et al. The role of [18F]fluoride positron emission tomography in the early detection of aseptic loosening of total knee arthroplasty. Int J Surg. 2007;5:99–104.PubMedCrossRef

12.

Ovadia D, Metser U, Lievshitz G, Yaniv M, Wientroub S, Even-Sapir E. Back pain in adolescents: assessment with integrated 18F-fluoride positron-emission tomography-computed tomography. J Pediatr Orthop. 2007;27:90–3.PubMedCrossRef

13.

Sörensen J, Michaelsson K, Strand H, Sundelin S, Rahme H. Long-standing increased bone turnover at the fixation points after anterior cruciate ligament reconstruction: a positron emission tomography (PET) study of 8 patients. Acta Orthop. 2006;77:921–5.PubMedCrossRef

14.

Dasa V, Adbel-Nabi H, Anders MJ, Mihalko WM. F-18 fluoride positron emission tomography of the hip for osteonecrosis. Clin Orthop. 2008;466:1081–6.PubMedCrossRef

15.

Rüdisüli A, Müller-Brand J. Spectrum of findings in SPECT-CT of the feet—a review of 54 patients with pain as the main referring symptom. Supplementum 47. Swiss Medical Forum. 10th Annual Congress of the Swiss Society Of Nuclear Medicine; 4–6 June 2009;9:21–2.

16.

Pagenstert GI, Barg A, Leumann AG, Rasch H, Müller-Brand J, Hintermann B, et al. SPECT-CT imaging in degenerative joint disease of the foot and ankle. J Bone Joint Surg Br 2009;91:1191–6.

17.

Perkins A, Hilson A, Hall J. Global shortage of medical isotopes threatens nuclear medicine services. BMJ. 2008;337:a1577.PubMedCrossRef

18.

Stafford N. Isotope shortage is limiting nuclear medicine across Europe. BMJ. 2008;337:a1575.PubMedCrossRef

19.

Pneumaticos SG, Chatziioannou SN, Hipp JA, Moore WH, Esses SI. Low back pain: prediction of short-term outcome of facet joint injection with bone scintigraphy. Radiology. 2006;238:693–8.PubMedCrossRef

20.

Zafra M, Ayala F, Gonzalez-Billalabeitia E, Vicente E, Gonzalez-Cabezas P, García T, et al. Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of medical oncology patients. Eur J Cancer. 2008;44:1678–83.PubMedCrossRef

21.

Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11:88–94.PubMedCrossRef

22.

Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and F-18-fluoride whole body PET: a feasible two-in-one approach to cancer imaging? Radiology. 1998;209:253–8.PubMed

23.

Hetzel M, Arslandemir C, König HH, Buck AK, Nüssle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18:2206–14.PubMedCrossRef

24.

Krug B, Van Zanten A, Pirson AS, Crott R, Borght TV. Activity-based costing evaluation of a 18F-fludeoxyglucose positron emission tomography study. Health Policy. 2009;92:234–43.

Titel: Therapeutic impact of [18F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain
verfasst von: Dorothee Rita Fischer
Gerardo J. Maquieira
Norman Espinosa
Marco Zanetti
Rolf Hesselmann
Anass Johayem
Thomas F. Hany
Gustav K. von Schulthess
Klaus Strobel
Publikationsdatum: 01.10.2010
Verlag: Springer-Verlag
Erschienen in: Skeletal Radiology / Ausgabe 10/2010
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI: https://doi.org/10.1007/s00256-010-0875-7

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Therapeutic impact of [¹⁸F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain